Clearmind Medicine Inc.
CMND Healthcare Biotechnology
In the quarter to July 2026, EPS grew 99.4%, free cash flow fell 77.9% and total debt rose 10,410.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CMND
Clearmind Medicine Inc. (CMND) Altman Z-score
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EOCN Eocene Ltd. compare | 26.9× |
| UNBX UNITY Biotechnology, Inc. compare | −5.6× |
| LIPO Lipella Pharmaceuticals Inc. compare | −10.7× |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | −15.9× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | −78.4× |
| CLDI Calidi Biotherapeutics, Inc. compare | −85.8× |
| IOBTQ IO Biotech, Inc. compare | — |
| PBLA Panbela Therapeutics Inc. compare | — |
| CMND Clearmind Medicine Inc. | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets